Iron in chronic brain disorders: Imaging and neurotherapeutic implications
暂无分享,去创建一个
Rohit Bakshi | Mohit Neema | R. Bakshi | M. Neema | J. Stankiewicz | A. Arora | C. Batt | Ashish Arora | James Stankiewicz | S. Panter | S. Scott Panter | Courtney E. Batt | S. Panter | Mohit Neema
[1] A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). The RANTTAS Investigators. , 1996, Stroke.
[2] Christian Gluud,et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. , 2007, JAMA.
[3] W Craelius,et al. Iron deposits surrounding multiple sclerosis plaques. , 1982, Archives of pathology & laboratory medicine.
[4] A. Koeppen,et al. The pathogenesis of superficial siderosis of the central nervous system , 1993, Annals of neurology.
[5] R. Brooks,et al. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. , 1999, Radiology.
[6] L. A. Hansen,et al. Suppression of hyperacute and passively transferred experimental autoimmune encephalomyelitis by the anti-oxidant, butylated hydroxyanisole , 1995, Journal of Neuroimmunology.
[7] M. Vérin,et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. , 2002, Journal of hepatology.
[8] R. Bakshi,et al. MRI in chronic toluene abuse: low signal in the cerebral cortex on T2-weighted images , 1998, Neuroradiology.
[9] M. Cotter,et al. Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. , 1995, The Journal of clinical investigation.
[10] M. Savoiardo. Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging , 2003, Neurological Sciences.
[11] S. LeVine,et al. Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice , 1998, Journal of Neuroimmunology.
[12] G A Johnson,et al. MRI of brain iron. , 1986, AJR. American journal of roentgenology.
[13] T. Kawanami,et al. Hereditary caeruloplasmin deficiency: clinicopathological study of a patient. , 1996, Journal of neurology, neurosurgery, and psychiatry.
[14] E. Haacke,et al. Imaging iron stores in the brain using magnetic resonance imaging. , 2005, Magnetic resonance imaging.
[15] S. LeVine,et al. Hemeoxygenase-1 in SJL mice with experimental allergic encephalomyelitis , 2003 .
[16] S. Benkovic,et al. Isoforms of ferritin have a specific cellular distribution in the brain , 1994, Journal of neuroscience research.
[17] P. Riederer,et al. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? , 1989, Acta neurologica Scandinavica. Supplementum.
[18] M. Argyropoulou,et al. T2 relaxation rate of basal ganglia and cortex in patients with β-thalassaemia major , 2001 .
[19] D. Richardson. Novel Chelators for Central Nervous System Disorders That Involve Alterations in the Metabolism of Iron and Other Metal Ions , 2004, Annals of the New York Academy of Sciences.
[20] J. Gutteridge,et al. Iron and oxygen radicals in brain , 1992, Annals of neurology.
[21] John F Schenck,et al. Magnetic resonance imaging of brain iron , 2003, Journal of the Neurological Sciences.
[22] D. Calne. The free radical hypothesis in idiopathic parkinsonism: Evidence against it , 1992, Annals of neurology.
[23] P. Doherty,et al. Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent , 1984, The Journal of experimental medicine.
[24] H. Schipper,et al. Proinflammatory cytokines promote glial heme oxygenase‐1 expression and mitochondrial iron deposition: implications for multiple sclerosis , 2001, Journal of neurochemistry.
[25] R. Gold,et al. The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis , 2004, Clinical and experimental immunology.
[26] P. Riederer,et al. Potential sources of increased iron in the substantia nigra of parkinsonian patients. , 2006, Journal of neural transmission. Supplementum.
[27] W. Rayens,et al. Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys , 2007, Neurobiology of Aging.
[28] D. Berg,et al. In vivo detection of iron and neuromelanin by transcranial sonography – a new approach for early detection of substantia nigra damage , 2006, Journal of Neural Transmission.
[29] Subramanian Rajagopalan,et al. Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease , 2003, Neuron.
[30] A. Blamire,et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. , 2005, Archives of neurology.
[31] M. Youdim,et al. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats , 2004, Neuropharmacology.
[32] P. Mantyh,et al. Aluminum, Iron, and Zinc Ions Promote Aggregation of Physiological Concentrations of β‐Amyloid Peptide , 1993, Journal of neurochemistry.
[33] G. Tocco,et al. Prevention and suppression of autoimmune encephalomyelitis by EUK-8, a synthetic catalytic scavenger of oxygen-reactive metabolites. , 1997, Cellular immunology.
[34] H. Miyajima,et al. Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate , 2007, Brain and Development.
[35] Glyn Johnson,et al. Magnetic field correlation imaging , 2006, Magnetic resonance in medicine.
[36] Yi Ai,et al. Correlation of R2 with total iron concentration in the brains of rhesus monkeys , 2005, Journal of magnetic resonance imaging : JMRI.
[37] J. Eaton,et al. Glycochelates and the etiology of diabetic peripheral neuropathy. , 2000, Free radical biology & medicine.
[38] J. Wilson,et al. Use of allopurinol and deferoxamine in cellular protection during ischemia. , 1992, Surgical neurology.
[39] B. Hallgren,et al. THE EFFECT OF AGE ON THE NON‐HAEMIN IRON IN THE HUMAN BRAIN , 1958, Journal of neurochemistry.
[40] S. Mandel,et al. Green tea polyphenol (–)‐epigallocatechin‐3‐gallate prevents N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced dopaminergic neurodegeneration , 2001, Journal of neurochemistry.
[41] R. A. Knight,et al. ASSESSMENT OF RELATIVE BRAIN IRON CONCENTRATIONS USING T-2-WEIGHTED AND T-2(ASTERISK)-WEIGHTED MRI AT 3-TESLA , 1994 .
[42] P. Harrison,et al. Evidence of H- and L-chains have co-operative roles in the iron-uptake mechanism of human ferritin. , 1992, The Biochemical journal.
[43] P. Crack,et al. Glutathione peroxidase 1 and glutathione are required to protect mouse astrocytes from iron‐mediated hydrogen peroxide toxicity , 2006, Journal of neuroscience research.
[44] J. Gitlin,et al. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[45] R. Bakshi,et al. FLAIR MRI of striatonigral degeneration , 2001, Neurology.
[46] Steven M LeVine,et al. Iron deposits in multiple sclerosis and Alzheimer's disease brains , 1997, Brain Research.
[47] W. D. Ehmann,et al. Brain trace elements in Alzheimer's disease. , 1986, Neurotoxicology.
[48] R. Medda,et al. The physiopathological significance of ceruloplasmin. A possible therapeutic approach. , 2000, Biochemical pharmacology.
[49] P D Griffiths,et al. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. , 2000, Brain : a journal of neurology.
[50] P. Riederer,et al. The possible role of iron in the etiopathology of parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.
[51] Jim Mintz,et al. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration , 2007, Neurobiology of Aging.
[52] C. Morris,et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease , 2001, Nature Genetics.
[53] M. I. Argyropoulou,et al. MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease , 2005, Journal of Neurology.
[54] E. Morgan,et al. Evidence for low molecular weight, non‐transferrin‐bound iron in rat brain and cerebrospinal fluid , 1998, Journal of neuroscience research.
[55] G. Sawle,et al. Palatal tremor and cognitive decline in neuroferritinopathy , 2002, Journal of neurology, neurosurgery, and psychiatry.
[56] R A Knight,et al. MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content. , 1999, Radiology.
[57] S. LeVine,et al. Heme oxygenase-1 in SJL mice with experimental allergic encephalomyelitis. , 2003, Multiple sclerosis.
[58] Rabi Tawil,et al. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. , 2005, Journal of neuropathology and experimental neurology.
[59] P. Boesiger,et al. T2 relaxation time in patients with Parkinson's disease , 1993, Neurology.
[60] C. W. Tjoa,et al. MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis , 2005, Journal of the Neurological Sciences.
[61] Peter Riederer,et al. Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.
[62] A. Moss,et al. Idebenone for treatment of Friedreich’s ataxia? , 2003, Neurology.
[63] E. Haley. High-dose tirilazad for acute stroke (RANTTAS II). RANTTAS II Investigators. , 1998, Stroke.
[64] J. R. Mitchell,et al. Deep grey matter `black T2` on 3 tesla magnetic resonance imaging correlates with disability in multiple sclerosis , 2007, Multiple sclerosis.
[65] M. Yorubulut,et al. T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores. , 2004, Neurology India.
[66] S W Atlas,et al. Deep gray matter hypointensity patterns with aging in healthy adults: MR imaging at 1.5 T. , 1991, Radiology.
[67] J. Keaney,et al. Iron Chelation Improves Endothelial Function in Patients With Coronary Artery Disease , 2001, Circulation.
[68] R. Crichton,et al. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. , 2002, Journal of inorganic biochemistry.
[69] C. Masters,et al. Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice , 2001, Neuron.
[70] G. Bartzokis,et al. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. , 2000, Archives of general psychiatry.
[71] Hisashi Tanaka,et al. Determination of transverse relaxation rate for estimating iron deposits in central nervous system , 2005, Neuroscience Research.
[72] Jim Mintz,et al. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases , 2005, Alzheimer's & Dementia.
[73] David Katz,et al. The relation between brain iron and NMR relaxation times: An in vitro study , 1996, Magnetic resonance in medicine.
[74] M. Récasens,et al. A transient treatment of hippocampal neurons with alpha-tocopherol induces a long-lasting protection against oxidative damage via a genomic action. , 2005, Free radical biology & medicine.
[75] Alberto Gatti,et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[76] G. Cohen,et al. Oxidative Stress, Mitochondrial Respiration, and Parkinson's Disease , 2000, Annals of the New York Academy of Sciences.
[77] W. Bradley,et al. Iron accumulation in the basal ganglia following severe ischemic-anoxic insults in children. , 1988, Radiology.
[78] S. LeVine,et al. Iron deposits in the central nervous system of SJL mice with experimental allergic encephalomyelitis. , 1998, Life sciences.
[79] P. Ponka. Hereditary Causes of Disturbed Iron Homeostasis in the Central Nervous System , 2004, Annals of the New York Academy of Sciences.
[80] M. Barcikowska,et al. Iron in parkinsonian and control substantia nigra—A mössbauer spectroscopy study , 1996, Movement disorders : official journal of the Movement Disorder Society.
[81] D. Birchall,et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. , 2006, Brain : a journal of neurology.
[82] R. Hider,et al. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy , 2005, British journal of pharmacology.
[83] C. Marsden,et al. INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN , 1987, The Lancet.
[84] Shawn K. Westaway,et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome , 2001, Nature Genetics.
[85] A. Mackay,et al. In vivo measurement of T2 distributions and water contents in normal human brain , 1997, Magnetic resonance in medicine.
[86] J. Eaton,et al. Exposure of endothelial cells to free heme potentiates damage mediated by granulocytes and toxic oxygen species. , 1991, Laboratory investigation; a journal of technical methods and pathology.
[87] Andrew J Wheaton,et al. T2ρ‐weighted contrast in MR images of the human brain , 2004, Magnetic resonance in medicine.
[88] R. Ordidge,et al. Assessment of relative brain iron concentrations using T2‐weighted and T2*‐weighted MRI at 3 Tesla , 1994, Magnetic resonance in medicine.
[89] J. Gitlin,et al. Use of desferrioxamine in the treatment of aceruloplasminemia , 1997, Annals of neurology.
[90] J. Pujol,et al. Biological significance of iron-related magnetic resonance imaging changes in the brain. , 1992, Archives of neurology.
[91] D. Ben-shachar,et al. The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons , 1991, Journal of neurochemistry.
[92] E. Hall. Novel inhibitors of iron‐dependent lipid peroxidation for neurodegenerative disorders , 1992, Annals of neurology.
[93] L. Kappelle,et al. Inhibition of Iron-Dependent and Ischemia-Induced Brain Damage by the α-Tocopherol Analogue MDL 74,722 , 1999, Experimental Neurology.
[94] P. Dash,et al. Deferoxamine improves spatial memory performance following experimental brain injury in rats , 1996, Brain Research.
[95] A. Mackinnon,et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. , 2003, Archives of neurology.
[96] B. Drayer,et al. Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content? , 1987, AJR. American journal of roentgenology.
[97] W. D. Ehmann,et al. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. , 1998, Neurotoxicology.
[98] S. Lynch,et al. A multiple course trial of desferrioxamine in chronic progressive multiple sclerosis. , 2000, Cellular and molecular biology.
[99] R. Ordidge,et al. Increased iron‐related MRI contrast in the substantia nigra in Parkinson's disease , 1995, Neurology.
[100] D. Patel,et al. Desmethyl tirilazad improves neurologic function after hypoxic ischemic brain injury in piglets , 2000, Critical care medicine.
[101] R. Uitti,et al. Regional Metal Concentrations in Parkinson's Disease, Other Chronic Neurological Diseases, and Control Brains , 1989, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[102] Virginia M. Y. Lee,et al. Increased Lipid Peroxidation Precedes Amyloid Plaque Formation in an Animal Model of Alzheimer Amyloidosis , 2001, The Journal of Neuroscience.
[103] R. Hauser,et al. Magnetic Resonance Imaging of Corticobasal Degeneration , 1996, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[104] R. Bakshi,et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. , 2002, Archives of neurology.
[105] J. Gitlin,et al. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. , 1998, The American journal of clinical nutrition.
[106] P Z Marmarelis,et al. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. , 1999, Magnetic resonance imaging.
[107] G. Bartzokis,et al. MR evaluation of age-related increase of brain iron in young adult and older normal males. , 1997, Magnetic resonance imaging.
[108] S. Robinson,et al. β-amyloid helps to protect neurons from oxidative stress , 2000, Neurobiology of Aging.
[109] J. Fernández-Real,et al. Blood letting in high-ferritin type 2 diabetes: effects on vascular reactivity. , 2002, Diabetes care.
[110] H. Rowley,et al. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. , 2006, AJNR. American journal of neuroradiology.
[111] D. McLachlan,et al. Intramuscular desferrioxamine in patients with Alzheimer's disease , 1991, The Lancet.
[112] E. Unger,et al. Toluene abuse: physical basis for hypointensity of the basal ganglia on T2-weighted MR images. , 1994, Radiology.
[113] T. Rouault,et al. Iron on the brain , 2001, Nature Genetics.
[114] T. Montine,et al. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[115] K. Krabbe,et al. Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[116] G. Perry,et al. Oxidative Stress and Redox‐Active Iron in Alzheimer's Disease , 2004, Annals of the New York Academy of Sciences.
[117] S. Fahn,et al. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.
[118] R. Llinas,et al. Superficial siderosis: a case report and review of the literature , 2007, Nature Clinical Practice Neurology.
[119] Christine D. Dijkstra,et al. Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats , 1995, Journal of Neuroimmunology.
[120] Mark Hallett,et al. Increased iron in the dentate nucleus of patients with Friedreich's ataxia , 1999, Annals of neurology.
[121] Ruitian Song,et al. Echo-spacing optimization for the simultaneous measurement of reversible (R2') and irreversible (R2) transverse relaxation rates. , 2007, Magnetic resonance imaging.
[122] P. Jenner. Oxidative stress as a cause of Parkinson's disease , 1991, Acta neurologica Scandinavica. Supplementum.
[123] D. Jiang,et al. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice , 2005, Journal of Neural Transmission.
[124] W H Oldendorf,et al. Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores , 1993, Magnetic resonance in medicine.
[125] Ashley I. Bush,et al. Redox-active iron mediates amyloid-β toxicity , 2001 .
[126] K. Uğurbil,et al. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts , 2007, Movement disorders : official journal of the Movement Disorder Society.
[127] M. Cotter,et al. Effects of an extracellular metal chelator on neurovascular function in diabetic rats , 2001, Diabetologia.
[128] C. Morris,et al. Iron and aluminium in relation to brain ferritin in normal individuals and Alzheimer's-disease and chronic renal-dialysis patients. , 1992, The Biochemical journal.
[129] F W Wehrli,et al. Method for image-based measurement of the reversible and irreversible contribution to the transverse-relaxation rate. , 1996, Journal of magnetic resonance. Series B.
[130] Mark A. Smith,et al. Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance , 2006, Neuroscience Letters.
[131] M. Youdim,et al. Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP‐induced striatal dopamine depletion , 2005, Journal of neurochemistry.
[132] Daniela Berg,et al. Iron metabolism in Parkinsonian syndromes , 2006, Movement disorders : official journal of the Movement Disorder Society.
[133] Ya Ke,et al. Iron misregulation in the brain: a primary cause of neurodegenerative disorders , 2003, The Lancet Neurology.
[134] D. Bennett,et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.
[135] M. Nahata,et al. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. , 2000, Drug safety.
[136] J. Koh,et al. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human β-amyloid precursor protein transgenic mice , 2004, Neurobiology of Aging.
[137] S. Chaturvedi. Clinical trials and financial reimbursement. , 1998, Stroke.
[138] Rohit Bakshi,et al. Magnetic Resonance Imaging of Iron Deposition in Neurological Disorders , 2006, Topics in magnetic resonance imaging : TMRI.
[139] H. Schipper. Heme Oxygenase‐1: Transducer of Pathological Brain Iron Sequestration under Oxidative Stress , 2004, Annals of the New York Academy of Sciences.
[140] L. Zecca,et al. Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability , 2006, Journal of Neural Transmission.
[141] C. Marsden,et al. Decreased Ferritin Levels in Brain in Parkinson's Disease , 1990, Journal of neurochemistry.
[142] V. Vassiliev,et al. Ceruloplasmin in neurodegenerative diseases , 2005, Brain Research Reviews.
[143] J. Reichenbach,et al. Theory and application of static field inhomogeneity effects in gradient‐echo imaging , 1997, Journal of magnetic resonance imaging : JMRI.
[144] D. Berg,et al. The basal ganglia in haemochromatosis , 2000, Neuroradiology.
[145] E. Hall,et al. Dextran-coupled deferoxamine improves outcome in a murine model of head injury. , 1992, Journal of neurotrauma.
[146] P. Burger,et al. MR detection of brain iron. , 1993, AJNR. American journal of neuroradiology.
[147] G. Bartzokis,et al. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. , 2000, Cellular and molecular biology.
[148] Rohit Bakshi,et al. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. , 2005, Archives of neurology.
[149] D. Bourdette,et al. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis , 2002, Journal of Neuroimmunology.
[150] P. Doherty,et al. Inhibition of allergic encephalomyelitis by the iron chelating agent desferrioxamine: differential effect depending on type of sensitizing encephalitogen , 1988, Journal of Neuroimmunology.
[151] J. Connor,et al. Relationship of iron to oligodendrocytes and myelination. , 1996, Glia.
[152] M. Argyropoulou,et al. T(2) relaxation rate of basal ganglia and cortex in patients with beta-thalassaemia major. , 2001, The British journal of radiology.
[153] C. Levenson. Iron and Parkinson's disease: chelators to the rescue? , 2003, Nutrition reviews.
[154] E. Shezen,et al. Oral administration of the oxidant-scavenger N-acetyl-l-cysteine inhibits acute experimental autoimmune encephalomyelitis , 1994, Journal of Neuroimmunology.
[155] R. Chanderbhan,et al. Prevention of post-ischemic brain lipid conjugated diene production and neurological injury by hydroxyethyl starch-conjugated deferoxamine. , 1992, Free radical biology & medicine.
[156] M. Youdim,et al. Nutritional Iron Deprivation Attenuates Kainate‐Induced Neurotoxicity in Rats: Implications for Involvement of Iron in Neurodegeneration , 2004, Annals of the New York Academy of Sciences.
[157] Raffaella Mariani,et al. MR imaging of cerebral cortical involvement in aceruloplasminemia. , 2005, AJNR. American journal of neuroradiology.
[158] Jim Mintz,et al. In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI , 1994, Biological Psychiatry.
[159] T. Montine,et al. Correlation of proton transverse relaxation rates (R2) with iron concentrations in postmortem brain tissue from alzheimer's disease patients , 2007, Magnetic resonance in medicine.
[160] J. Andersen. Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease? , 2001, Novartis Foundation symposium.
[161] R. Fariello,et al. A proposed dual role of neuromelanin in the pathogenesis of Parkinson’s disease , 2006, Neurology.
[162] J. Connor,et al. Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.
[163] P. Kloetzel,et al. Green Tea Epigallocatechin-3-Gallate Mediates T Cellular NF-κB Inhibition and Exerts Neuroprotection in Autoimmune Encephalomyelitis1 , 2004, The Journal of Immunology.
[164] R. Martins,et al. Quantitative MR imaging R2 relaxometry in elderly participants reporting memory loss. , 2006, AJNR. American journal of neuroradiology.
[165] C. Morris,et al. Brain iron homeostasis. , 1992, Journal of inorganic biochemistry.
[166] R. Bakshi,et al. Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis , 2006, Multiple sclerosis.
[167] J. Pickard,et al. A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. , 1999, Journal of neurosurgery.
[168] L. Beckman,et al. Transferrin C2, metal binding and Alzheimer's disease , 1998, Neuroreport.
[169] K. Pantopoulos. Iron Metabolism and the IRE/IRP Regulatory System: An Update , 2004, Annals of the New York Academy of Sciences.
[170] John F. Schenck,et al. Imaging of brain iron by magnetic resonance: T2 relaxation at different field strengths , 1995, Journal of the Neurological Sciences.
[171] J. Connor,et al. Regional distribution of iron and iron‐regulatory proteins in the brain in aging and Alzheimer's disease , 1992, Journal of neuroscience research.
[172] P Woodbury,et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.
[173] R. Bakshi,et al. T1‐ and T2‐Based MRI Measures of Diffuse Gray Matter and White Matter Damage in Patients with Multiple Sclerosis , 2007, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[174] J. Connor,et al. Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains , 1990, Journal of neuroscience research.
[175] C. Olanow,et al. Oxidative stress and the pathogenesis of Parkinson's disease , 1996, Neurology.
[176] R. Henkelman,et al. T2 values in the human brain: comparison with quantitative assays of iron and ferritin. , 1989, Radiology.
[177] R. Shin,et al. A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated τ of Alzheimer’s disease , 2003, Brain Research.
[178] M. Núñez,et al. Antioxidant responses of cortex neurons to iron loading. , 2006, Biological research.
[179] R Bakshi,et al. MRI T2 shortening (‘black T2’) in multiple sclerosis: frequency, location, and clinical correlation , 2000, Neuroreport.
[180] J. Connor,et al. Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions , 1995, Journal of neurochemistry.
[181] S. Hayflick. Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase–associated neurodegeneration is the name . . . , 2003, Current opinion in pediatrics.
[182] H. Fenton,et al. LXXIII.—Oxidation of tartaric acid in presence of iron , 1894 .
[183] Neha Singh,et al. Advances in the treatment of Parkinson's disease , 2007, Progress in Neurobiology.
[184] F. Foury,et al. A non-essential function for yeast frataxin in iron-sulfur cluster assembly. , 2002, Human molecular genetics.
[185] E M Haacke,et al. An MRI method for measuring T2 in the presence of static and RF magnetic field Inhomogeneities , 1997, Magnetic resonance in medicine.